Immunotherapeutic approaches in chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 49, Issue 4, 2008, Pages 629-634

  Guilhot, François ^a   Roy, Lydia ^a   Saulnier, Pierre Jean ^a   Guilhot, Joëlle ^a   Barra, Anne ^a   Gombert, Jean Marc ^a   Turhan, Ali ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic myelogenous leukemia; Imatinib; Immunotherapy; Interferon

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BCR ABL PROTEIN; CANCER VACCINE; CD34 ANTIGEN; CD8 ANTIGEN; CMLVAX 100; CYTARABINE; HEAT SHOCK PROTEIN 70; IMATINIB; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; MINOR HISTOCOMPATIBILITY ANTIGEN; ONCOPROTEIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEPTIDE VACCINE; QS 21; QS 2117; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ALPHA2C INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CD34 SELECTION; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; IMMUNOREGULATION; LEUKEMOGENESIS; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; VACCINES;

EID: 42049120548     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801927510     Document Type: Conference Paper

References (32)

1. Molldrem, J. J., Lee, P. P., Wang, C., Felio, K., Kantarjian, H. M. and Champlin, R. E. (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med, 6, pp. 1018-1023.
2. Gannage, M., Abel, M., Michallet, A. S., Delluc, S., Lambert, M. and Giraudier, S. (2005) Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol, 174, pp. 8210-8218.
3. Bocchia, M., Wentworth, P. A., Southwood, S., Sidney, J., McGraw, K. and Scheinberg, D. A. (1995) Specific binding of leukemia oncogene fusion protein peptides to HLA Class I molecules. Blood, 85, pp. 2680-2684.
4. Bocchia, M., Korontsvit, T., Xu, Q., Mackinnon, S., Yang, S. Y. and Sette, A. (1996) Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood, 87, pp. 3587-3592.
5. Yotnda, P., Firat, P., Garcia-Pons, F., Garcia, Z., Gourru, G. and Vernant, J. P. (1998) Cytotoxic T-cell response against the chimeric p210 BCRABL protein in patients with chronic myelogenous leukemia. J Clin Invest, 101, pp. 2290-2296.
6. Buzyn, A., Ostankovitch, M., Zerbib, A., Kemula, M., Connan, F. and Varet, B. (1997) Peptides derived from the whole sequence of BCRABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol, 27, pp. 2066-2072.
7. Clark, R. E., Dodi, I. A., Hill, S. C., Lill, J. R., Aubert, G. and MacIntyre, A. R. (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood, 98, pp. 2887-2893.
8. Posthuma, E FM, Falkenburg, J HF and Apperley, J. F. (1999) HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukaemia. Blood, 93, pp. 3863-3865.
9. Pinilla-Ibarz, J., Cathcart, K., Korontsvit, T., Soignet, S., Bocchia, M. and Caggiano, J. (2000) Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune response. Blood, 95, pp. 1781-1787.
10. Cathcart, K., Pinilla-Ibarz, J., Korontsvit, T., Schwartz, J., Zakhaleva, V. and Papadopoulos, E. B. (2003) A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood, 103, pp. 1037-1042.
11. Bocchia, M., Gentili, S., Abruzzese, E., Fanelli, A., Iuliano, F. and Tabilio, A. (2005) Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: A multicentre observational trial. Lancet, 365, pp. 657-662.
12. Li, A., Qiao, Y., Liu, B., Laska, E. J., Chakravarthi, P. and Kulko, J. M. (2005) Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia. Clin Cancer Res, 11, pp. 4460-4468.
13. Gutterman, J. U. (1994) Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci USA, 91, pp. 1198-1205.
14. Harada, H., Taniguchi, T. and Tanaka, N. (1998) The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie, 80, pp. 641-650.
15. Schmidt, M., Nagel, S., Proba, J., Thiede, C., Ritter, M. and Waring, J. F. (1998) Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood, 91, pp. 22-29.
16. Schmidt, M., Hochhaus, A., Nitsche, A., Hehlmann, R. and Neubauer, A. (2001) Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α. Blood, 97, pp. 3648-3650.
17. Hao, S. X. and Ren, R. (2000) Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol, 20, pp. 1149-1161.
18. Holtschke, T., Lohler, J., Kanno, Y., Fehr, T., Giese, N. and Rosenbauer, F. (1996) Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell, 87, pp. 307-317.
19. Tsujimura, H., Tamura, T. and Ozato, K. (2003) Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells. J Immunol, 170, pp. 1131-1135.
20. Silver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J. and Bennett, C. (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology. Blood, 94, pp. 1517-1536.
21. Bonifazi, F., de Vivo, A., Rosti, G., Guilhot, F., Guilhot, J. and Trabacchi, E. (2001) Chronic myeloid leukemia and interferon-α: A study of complete cytogenetic responders. Blood, 98, pp. 3074-3081.
22. Baccarani, M., Rosti, G., de Vivo, A., Bonifazi, F., Russo, D. and Martinelli, G. (2002) A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood, 99, pp. 1527-1535.
23. Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J. L. and Maloisel, F. (1997) Interferon alfa-2B combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med, 337, pp. 223-229.
24. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M. and Cervantes, F. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med, 348, pp. 994-1004.
25. Roy, L., Guilhot, J., Krahnke, T., Guerci-Bresler, A., Druker, B. J. and Larson, R. A. (2006) Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: Historical comparison between two phase 3 trials. Blood, 108, pp. 1478-1484.
26. Hochhaus, A., Kreil, S., Corbin, A. S., La Rosee, P., Muller, M. C. and Lahaye, T. (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16, pp. 2190-2196.
27. Lucy, J. E., Jorgensen, H. G., Mountford, J. C. and Holyoake, T. L. (2005) Punish the parent not the progeny. Blood, 105, pp. 1862-1866.
28. Sorel, N., Bonet, M. L., Guillier, M., Guilhot, F., Brizard, A. and Turhan, A. G. (2004) Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res, 323, pp. 728-730.
29. Lipton, J. H., Khoroshko, N. D., Golenkov, A. K., Abdulkadyrov, K. M., Nair, K. M. and Raghunadharao, D. (2003) The Pegasys CML Study Group. Two-year survival data from a randomized study of peginterferon alfa-2a(40KD) vs interferon alfa-2a in patients with chronic phase chronic myelogenous leukemia. Blood, 102, p. 3363a.
30. Baccarani, M., Martinelli, G., Rosti, G., Trabacchi, E., Testoni, N. and Bassi, S. (2004) Imatinib an pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. Blood, 104, pp. 4245-4251.
31. Berger, U., Hochhaus, A., Pfirrmann, M., Schoch, C., Reiter, A. and Ehninger, G. (2005) Concept, feasibility and results of the randomized comparison of imatinib combination therapies for chronic myeloid leukemia: The german CML-study IV. Blood, 106, p. 1083a.
32. Guerci, A., Nicolini, F., Maloisel, F., Corm, S., Legros, L. and Rigal-Huguet, F. (2005) Randomized comparison of imatinib with imatinib combination therapies in newly diagnosed chronic myelogenous leukaemia patients in chronic phase: Design and first interim analysis of a phase III trial from the French CML group. Blood, 106, p. 168a.